Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a single transaction involving the acquisition of Ordinary Shares.
| Metric | Value |
|---|---|
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Type | Acquisition via ShareSave Plan option exercise |
| Volume | 744 shares |
| Price per Share | £12.09 |
| Transaction Date | February 25, 2022 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It documents a routine executive compensation event.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed by Ms. E. Walmsley, Chief Executive Officer, following the exercise of options granted on November 29, 2018.
Key Facts for Investor Verification
- Insider Activity: CEO Emma Walmsley acquired 744 shares at a fixed option price of £12.09.
- Plan Details: The transaction occurred under the Company's ShareSave Plan.
- Timing: The transaction date was February 25, 2022, reported in the March 2022 filing.
- Scope Limitation: This document does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance data.